{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-002679","form_type":"8-K","ticker":"PEPG","cik":"0001835597","company_name":"PepGen Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.862684+00:00","generated_at":"2026-06-07T02:33:58.697534+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"PepGen doses first patient in Phase 2 CONNECT1-EDO51 trial for Duchenne muscular dystrophy","bullets":["First patient dosed in open-label, multiple ascending dose Phase 2 trial of PGN-EDO51 in DMD patients amenable to exon 51 skipping.","Trial enrolls ~10 male patients aged >=8 years; starting dose 5 mg/kg escalating to 10 mg/kg pending safety.","Preliminary data from the 5 mg/kg cohort expected mid-2024: safety, exon skipping, and dystrophin production.","Phase 1 healthy volunteers showed peak exon 51 skipping of 3.8% after single 10 mg/kg dose; 100% had skipping.","PGN-EDO51 was generally well-tolerated through 15 mg/kg in Phase 1; trial ID NCT06079736."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-002679","json":"https://secwatch.observer/filing/0000950170-24-002679.json","markdown":"https://secwatch.observer/filing/0000950170-24-002679.md","text":"https://secwatch.observer/filing/0000950170-24-002679.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835597/000095017024002679/0000950170-24-002679-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835597/000095017024002679/pepg-20240108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:33:58.697534+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}